Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking
Eldehna, Wagdy M; Fares, Mohamed; Ibrahim, Hany S; Aly, Mohamed H; Zada, Suher; Ali, Mamdouh M; Abou-Seri, Sahar M; Abdel-Aziz, Hatem A; Abou El Ella, Dalal;
Abstract
In our effort to develop potent and effective agents with anti-proliferative activity towards HepG2 hepatocellular carcinoma cells with potential inhibitory activity against VEGFR-2, a novel series of 1-(4-((2-oxoindolin-3-ylidene)amino)phenyl)-3-arylureas was designed and synthesized. All the newly prepared ureas 9a-x were evaluated in vitro for their anti-proliferative activity against HepG2 hepatocellular carcinoma cell line. Compounds 9a-c, 9e, 9f, 9j, 9m-o, 9t-v and 9x exhibited good activity against HepG2 cancer cells (IC50 = 1.22 ± 0.11-8.37 ± 0.85 μM) comparable to that of doxorubicin and sorafinib (IC50 = 2.90 ± 0.36 and 3.40 ± 0.25 μM, respectively). These thirteen compounds were further evaluated for their inhibitory activity against VEGFR-2. Compound 9x emerged as the most active counterpart against VEGFR-2 with IC50 value of 0.31 ± 0.04 μM. Furthermore, a molecular docking of the tested compounds was carried out in order to investigate their binding pattern with the prospective target, VEGFR-2 (PDB-code: 4ASD).
Other data
Title | Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking | Authors | Eldehna, Wagdy M; Fares, Mohamed; Ibrahim, Hany S; Aly, Mohamed H; Zada, Suher; Ali, Mamdouh M; Abou-Seri, Sahar M; Abdel-Aziz, Hatem A; Abou El Ella, Dalal | Keywords | Design; Docking; HepG2; Urea; VEGFR-2 | Issue Date | 15-Jul-2015 | Journal | European journal of medicinal chemistry | ISSN | 02235234 | DOI | 10.1016/j.ejmech.2015.05.040 | PubMed ID | 26071861 | Scopus ID | 2-s2.0-84931281941 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.